Martine Rothblatt Sells 9,500 Shares of United Therapeutics (NASDAQ:UTHR) Stock

United Therapeutics Corporation (NASDAQ:UTHR) CEO Martine Rothblatt sold 9,500 shares of the company’s stock in a transaction on Friday, August 28th. The stock was sold at an average price of $517.51, for a total transaction of $4,916,345.00. Following the sale, the chief executive officer directly owned 324,443 shares in the company, valued at $167,902,496.93. This trade represents a 2.84% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this link.

United Therapeutics Price Performance

UTHR stock traded down $5.08 during trading hours on Monday, reaching $510.38. The stock had a trading volume of 536,220 shares, compared to its average volume of 488,973. The stock has a 50-day simple moving average of $530.46 and a 200 day simple moving average of $539.16. United Therapeutics Corporation has a fifty-two week low of $303.08 and a fifty-two week high of $609.35. The stock has a market capitalization of $21.89 billion, a PE ratio of 18.26, a price-to-earnings-growth ratio of 1.75 and a beta of 0.59.

United Therapeutics (NASDAQ:UTHR) last released its quarterly earnings data on Wednesday, August 5th. The biotechnology company reported $7.27 earnings per share for the quarter, topping the consensus estimate of $6.86 by $0.41. The company had revenue of $783.30 million for the quarter, compared to analyst estimates of $804.65 million. United Therapeutics had a net margin of 41.56% and a return on equity of 20.18%. United Therapeutics’s revenue for the quarter was down 1.9% compared to the same quarter last year. During the same period in the previous year, the business earned $6.41 EPS. On average, sell-side analysts forecast that United Therapeutics Corporation will post 26.33 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of brokerages have weighed in on UTHR. TD Cowen reissued a “buy” rating on shares of United Therapeutics in a research report on Thursday, May 21st. Royal Bank Of Canada cut their price objective on United Therapeutics from $704.00 to $677.00 and set an “outperform” rating for the company in a research report on Thursday, August 6th. Morgan Stanley set a $515.00 target price on United Therapeutics in a research note on Thursday, August 6th. Bank of America decreased their target price on United Therapeutics from $620.00 to $613.00 and set a “neutral” rating on the stock in a report on Friday, July 10th. Finally, JPMorgan Chase & Co. increased their price target on United Therapeutics from $685.00 to $687.00 and gave the company an “overweight” rating in a research note on Thursday, July 23rd. Eleven analysts have rated the stock with a Buy rating and two have issued a Hold rating to the company’s stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $646.00.

Institutional Trading of United Therapeutics

Several large investors have recently bought and sold shares of the business. Toth Financial Advisory Corp lifted its holdings in shares of United Therapeutics by 2,400.0% in the second quarter. Toth Financial Advisory Corp now owns 50 shares of the biotechnology company’s stock worth $27,000 after acquiring an additional 48 shares during the last quarter. Fiduciary Financial Advisors acquired a new position in United Therapeutics during the 2nd quarter worth approximately $30,000. WealthCollab LLC lifted its stake in United Therapeutics by 55.9% in the 2nd quarter. WealthCollab LLC now owns 106 shares of the biotechnology company’s stock valued at $30,000 after purchasing an additional 38 shares during the last quarter. Rakuten Securities Inc. lifted its stake in United Therapeutics by 76.7% in the 2nd quarter. Rakuten Securities Inc. now owns 106 shares of the biotechnology company’s stock valued at $30,000 after purchasing an additional 46 shares during the last quarter. Finally, Entrust Financial LLC acquired a new stake in United Therapeutics in the fourth quarter valued at approximately $31,000. 94.08% of the stock is owned by institutional investors and hedge funds.

United Therapeutics Company Profile

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.